ArticleCancers2021

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor.

Leonie D H Gossel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.